A Scaled CRDMO Platform Delivering Sustainable High Growth Use of Adjusted Financial Measures (Non-IFRS Measures) We have provided adjusted net profit, adjusted net profit margin, adjusted gross profit, adjusted gross profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required ...

Core Points - Amgen announced a $900 million expansion of its manufacturing facility in Ohio, increasing total investment in Central Ohio to over $1.4 billion and creating 750 jobs [1][2] - The expansion is part of Amgen's commitment to U.S. manufacturing and aims to enhance its global biomanufacturing network [2][4] - Since the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5 billion in the U.S., generating an estimated $12 billion in additional economic output [3] Company Overview - Amgen has been a leader in biologic medicine manufacturing since 1988 and emphasizes innovation and access to medicines for patients worldwide [2][5] - The company has a strong pipeline targeting various diseases, including cancer and heart disease, and has received multiple accolades for its innovation and workplace environment [6] Economic Impact - Ohio's supportive business climate and skilled workforce have made it an attractive location for Amgen's investments, contributing to the state's economic development [3] - The expansion in Ohio follows a recent announcement of a $1 billion investment for a second manufacturing plant in Holly Springs, NC, indicating a broader strategy to enhance U.S. manufacturing capabilities [4]